Episode Details

Back to Episodes

SGEM#518: What Have You Done for Me Lately – Oseltamivir for Hospitalized Patients?

Published 2 months, 4 weeks ago
Description
Date: August 23, 2026 Guest Skeptic: Dr. Roya Caloia is a former EM program director, longtime faculty at Henry Ford Genesys and current interim Associate Medical Director. She is also the Chairperson of the National Clinical Governance Board for US Acute Care Solutions Case: A 62-year-old woman with diabetes and chronic lung disease presents to the emergency department (ED) with five days of fever, cough, myalgias and progressively worsening dyspnea. Her respiratory rate is 34 breaths per minute, oxygen saturation is 82% on room air, and chest imaging shows bilateral air-space disease. Molecular testing is positive for influenza A. Despite supplemental oxygen, she requires high-flow nasal oxygen at 50 L/min with an FiO₂ of 0.60. Following initial fluids, her blood pressure remains low, and norepinephrine is started. She has received no more than one dose of oseltamivir before arrival. The ICU team is contacted, and the question is whether she should receive enteral oseltamivir for five days, ten days, or no influenza antiviral. Background: Influenza season has a way of turning the ED waiting room into a coughing convention. Most patients feel miserable but recover with time and supportive care. The concern is the smaller group at higher risk of complications, or those already sick enough to require hospital admission. That is usually when someone asks the annual question: Should we give Tamiflu?  Centers for Disease Control and Prevention (CDC) says: “For hospitalized patients with suspected or confirmed influenza, initiation of antiviral treatment with oral or enterically administered oseltamivir is recommended as soon as possible. Antiviral treatment might be effective in reducing morbidity and mortality in hospitalized influenza patients, especially adults, even if treatment is started more than 48 hours after onset of illness.” For those outside the United States, the World Health Organization (WHO) guideline specifically addresses severely ill and critically ill patients. The WHO guideline recommends oseltamivir for patients with severe influenza and even suggests considering extending treatment from 5 to 10 days in critically ill patients. Oseltamivir, better known by the brand name Tamiflu, is an oral neuraminidase inhibitor active against influenza A and B. It blocks an enzyme the virus uses to release newly formed viral particles from infected cells and spread to other cells. Put another way, oseltamivir tries to stop the flu from going viral (dad joke). The usual adult treatment is 75 mg twice daily for five days, with dose adjustment for renal impairment. The regulatory indication focuses on acute, uncomplicated influenza when treatment starts within 48 hours, but clinical guidelines recommend starting it as soon as possible in hospitalized patients, even when they present later in the illness. The challenge is that a biologically plausible mechanism does not automatically produce a patient-oriented outcome (POO). In otherwise uncomplicated influenza, oseltamivir appears to shorten symptoms by about 17 hours on average. That could mean feeling better Tuesday evening instead of Wednesday morning. It has not convincingly reduced hospital admission in outpatient trials, and it does increase nausea and vomiting. Headache and neuropsychiatric events have also been part of the safety discussion, although the causal relationship for the latter remains uncertain. Tamiflu has also been at the centre of one of medicine’s biggest data-transparency battles [1,2].  Much of the phase III evidence supporting oseltamivir had not been published, and independent Cochrane reviewers spent years trying to obtain the full clinical study reports from Roche, the manufacturer. The BMJ’s Open Data campaign helped keep the pressure on until the reports were eventually released. When the Cochrane team examined the more complete record, the benefits appeared smaller and the harms more apparent [3]. This became a cautionary tale about publ
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us